Summary/Abstract for Overall Program
The long-term objective of this program project is to determine how herpes simplex virus
1 (HSV-1) can switch between a highly active "lytic" infection that produces infectious
virus and a more silent latent infection. There are several hypotheses regarding
mechanisms that can tilt the balance in favor of lytic infection or latent infection. These
mechanisms include viral gene products that affect the chromatin status of the viral
genome, post-transcriptional mechanisms that can affect viral and host gene expression,
and immune responses and viral gene products that combat those responses. None of
these mechanisms is solely responsible for the lytic/latent balance, and each of these
mechanisms is highly likely to be connected. For example, immune responses can affect
viral gene expression, and post-transcriptional mechanisms can repress the expression
of viral gene products that affect chromatin status and combat immune responses. Thus,
an integrated approach to the lytic/latent balance is needed. In this Program Project
proposal, three senior herpesvirologists with complementary areas of expertise will
conduct a series of highly collaborative studies to investigate these mechanisms in three
intertwined projects with the aid of three cores.
Project 1 will study (including collaborative studies with Project 2) how viral latency-
associated transcripts (LATs), the viral protein ICP0, and the host protein CTCF effect a
chromatin configuration poised for reactivation during establishment and maintenance of
latency in vivo, and with Project 3, in cultured mouse neurons, and in human neurons.
Project 2 will focus on how post-transcriptional regulatory mechanisms can repress lytic
gene expression and affect chromatin status (with Project 1) and a viral gene product
that counteracts immunity (with Projects 3 and 1) and contribute to latency, and a virus
block to nuclear export of miRNAs (with Project 1) and the targets of viral miRNAs in
cultured cells including mouse and human neurons (Projects 3 and 1).
Project 3 will use an in vitro model of latency using cultured neurons from mice, including
genetically altered strains, and viral mutants (some from Projects 1 and 2) to test roles of
neuron-specific autophagosomes, viral proteins that counter immunity, and antibodies in
the nervous system (including those generated by a vaccine from Project 1) in control of
viral replication, latency, reactivation, and, gene expression.
Public Health Relevance Statement
Program Project Narrative
Herpes simplex virus (HSV) directly causes widespread disease including keratitis and,
rarely, encephalitis that can be life-threatening, and HSV is associated with Alzheimer’s
disease and other neurodegenerative disease. Most HSV disease occurs following
reactivation from latent infection. Thus, the proposed studies on the host and viral
factors that contribute to HSV latency are highly relevant to both virus biology and
human disease and may lead to strategies for preventing, treating, and/or curing HSV
infections.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
047006379
UEI
JDLVAVGYJQ21
Project Start Date
02-July-2013
Project End Date
31-July-2024
Budget Start Date
01-August-2019
Budget End Date
31-July-2020
Project Funding Information for 2019
Total Funding
$2,164,748
Direct Costs
$1,511,359
Indirect Costs
$653,389
Year
Funding IC
FY Total Cost by IC
2019
National Institute of Allergy and Infectious Diseases
$2,164,748
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2P01AI098681-06A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2P01AI098681-06A1
Patents
No Patents information available for 2P01AI098681-06A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2P01AI098681-06A1
Clinical Studies
No Clinical Studies information available for 2P01AI098681-06A1
News and More
Related News Releases
No news release information available for 2P01AI098681-06A1
History
No Historical information available for 2P01AI098681-06A1
Similar Projects
No Similar Projects information available for 2P01AI098681-06A1